Coenzyme Q10 (
CoQ10) deficiency (MIM 607426) causes a mitochondrial syndrome with variability in the clinical presentations. Patients with
CoQ10 deficiency show inconsistent responses to oral ubiquinone-10 supplementation, with the highest percentage of unsuccessful results in patients with neurological symptoms (
encephalopathy,
cerebellar ataxia or multisystemic disease). Failure in the ubiquinone-10 treatment may be the result of its poor absorption and bioavailability, which may be improved by using different pharmacological formulations. In a mouse model (
Coq9(X/X)) of
mitochondrial encephalopathy due to
CoQ deficiency, we have evaluated oral supplementation with water-soluble formulations of reduced (ubiquinol-10) and oxidized (ubiquinone-10) forms of
CoQ10. Our results show that
CoQ10 was increased in all tissues after supplementation with ubiquinone-10 or
ubiquinol-10, with the tissue levels of
CoQ10 with
ubiquinol-10 being higher than with ubiquinone-10. Moreover, only
ubiquinol-10 was able to increase the levels of
CoQ10 in mitochondria from cerebrum of
Coq9(X/X) mice. Consequently,
ubiquinol-10 was more efficient than ubiquinone-10 in increasing the animal
body weight and CoQ-dependent respiratory chain complex activities, and reducing the vacuolization,
astrogliosis and oxidative damage in diencephalon, septum-striatum and, to a lesser extent, in brainstem. These results suggest that water-soluble formulations of
ubiquinol-10 may improve the efficacy of
CoQ10 therapy in primary and secondary
CoQ10 deficiencies, other
mitochondrial diseases and
neurodegenerative diseases.